Резолюция Совета экспертов «Дисбиоз. Ближайшие и отдаленные последствия нарушения микробиома и варианты их коррекции с помощью пробиотиков»

Abstract

The appearance of new high-tech microbiological research methods has significantly changed the understanding of the human microbiome. The purpose of the meeting of the Council of Experts "Dysbiosis. The immediate and long-term consequences of microbiome disorders and options for their correction with probiotics" was the definition of modern positions about possible methods of studying the intestinal microbiome, the possibilities of correcting dysbiosis, the use of Saccharomyces Boulardii CNCM I-745 to correct microbiome disorders in various clinical situations. The microbiota of the large intestine is represented by more than 1000 species of 7 different phyla of the Bacteriae domain, up to 160 numerically prevailing species are detected in one individual. The criteria of the microbiological "norm" for the intestinal microbiome have not been definitively established. To study the microbiome, a set of methods is used that combine cultural and molecular genetic methods that complement each other. Currently, none of the methods is widely available in clinical practice. To study the functional state of the intestinal microbiota, the most accessible is breath testing. Currently, there are no clinical markers of dysbiosis, and laboratory markers of dysbiosis require modification. There is an insignificant spectrum of diseases with such markers: acute intestinal infections, antibiotic-associated C. difficile-diarrhea, IBD, IBS. Probiotics can provide restoration of the intestinal microbiota. The effectiveness and safety of the use of S. boulardii CNCM I-745 for this purpose has been proven. In the case of acute intestinal infection, antibiotic-associated diarrhea, and the consequences of HP infection eradication, studies have a high level of evidence, and the use of Sb CNCM I-745 for treating IBS and IBD in children is promising.